Lipoprotein(a) Lowering Therapies Market to Reach USD 2.20 Billion by 2036 at 8.8% CAGR; USA Leads Country Growth at 10.6%, Germany Trails at 6.6%

NEWARK, Del., Sept. 24, 2026 - According to Future Market Insights, the global lipoprotein(a) lowering therapies market is projected to increase from USD 946.0 million in 2026 to USD 2,198.8 million by 2036, expanding at a CAGR of 8.8% during the forecast period. The market is expected to add USD 1,252.8 million in value between 2026 and 2036. Demand is being shaped by specialist interest in therapies that suppress hepatic apolipoprotein(a), alongside growing clinical research into durable RNA-based medicines.

👉 Get Detailed Market Forecasts, Competitive Benchmarking, and Pricing Trends:
https://www.futuremarketinsights.com/reports/sample/rep-gb-34122

Global Segment Leaders

· Therapy Type - Antisense Oligonucleotides: 41.1% share in 2026. ASOs support sequence-specific messenger RNA suppression and have established clinical development and dosing evidence.

· Target - LPA Gene: 32.3% share in 2026. The LPA gene directly controls hepatic apolipoprotein(a) production, making it a central target for selective gene-expression approaches.

· Indication - Atherosclerotic Cardiovascular Disease: 34.2% share in 2026. Defined cardiovascular endpoints and identifiable high-risk populations support clinical evaluation of Lp(a) reduction.

· End User - Hospitals: 33.2% share in 2026. Hospitals combine specialist cardiology services with lipid testing, cardiovascular imaging, and clinical-trial monitoring.

Country-Level Performance

· USA - 10.6% CAGR: Extensive cardiovascular outcome research and specialist lipid infrastructure are supporting clinical-trial participation and patient identification.

· UK - 10.1% CAGR: Organized specialist lipid pathways connect laboratory measurement with secondary-prevention reviews among high-risk populations.

· Japan - 9.4% CAGR: Tertiary hospital concentration and established laboratory testing pathways support inherited-risk assessment and specialist treatment introduction.

· South Korea - 7.8% CAGR: Tertiary referral expansion and specialist lipid guidance are supporting risk assessment and treatment readiness.

· Germany - 6.6% CAGR: Established apheresis services provide a treatment pathway as pharmacological approaches to elevated Lp(a) develop.

FMI's country forecasts cover 2026 to 2036, with the profiled markets ranging from 6.6% CAGR in Germany to 10.6% in the USA.

Regional Context

The USA records the highest CAGR among FMI's five profiled markets at 10.6%, followed by the UK at 10.1% and Japan at 9.4%. South Korea is projected to expand at 7.8%, while Germany records 6.6%.

The full report covers North America, Latin America, Europe, East Asia, South Asia, Oceania, and the Middle East and Africa. Country-level coverage specifically includes the USA, UK, Japan, South Korea, Germany, China, and India, with 30+ countries included in the broader analysis.

Market Drivers, Restraints and Opportunities

Inherited cardiovascular risk and emerging clinical evidence are increasing specialist interest in targeted Lp(a)-lowering therapies. FMI notes that dedicated medicines can provide deeper Lp(a) suppression than conventional lipid treatments in genetically elevated-risk populations, while measurable biomarker responses support treatment evaluation.

A central restraint is the need for cardiovascular outcome evidence before broader prescribing. Clinicians and payers are evaluating whether reductions in Lp(a) translate into meaningful reductions in cardiovascular events. Variable testing practices can also delay consistent identification of patients who may qualify for treatment.

Testing programs represent an opportunity to create more clearly identifiable treatment populations. Structured pathways connecting laboratory Lp(a) measurement with specialist cardiovascular review can help move patients from risk identification toward treatment assessment. Oral treatment formats also broaden potential options for patients who prefer daily administration.

Recent clinical evidence continues to shape the market. FMI cites the American Heart Association's March 2026 update that Lp(a) concentrations of 250 nmol/L are associated with at least a two-fold increased long-term risk of heart attack or stroke.

👉 Access the Complete Report in PDF Format:
https://www.futuremarketinsights.com/reports/brochure/rep-gb-34122

Competitive Landscape

The competitive landscape centers on Novartis AG, Eli Lilly and Company, Amgen Inc., Ionis Pharmaceuticals, Inc., and Silence Therapeutics plc. FMI's competitive benchmarking evaluates these companies across portfolio depth, clinical match, service support, and geographic reach.

Novartis is developing pelacarsen across cardiovascular outcome and calcific valve disease programs. Eli Lilly is advancing lepodisiran and muvalaplin across injectable and oral formats. Amgen is progressing olpasiran across prevention studies, while Ionis Pharmaceuticals contributes antisense development expertise and Silence Therapeutics focuses on small interfering RNA development.

Key Developments

· March 2025: Eli Lilly announced positive ALPACA results for lepodisiran in adults with elevated Lp(a), supporting continued development of long-duration dosing.

· August 2025: Novartis announced presentation of Lp(a)FRONTIERS APHERESIS study data at the European Society of Cardiology Congress, evaluating pelacarsen in the context of reducing dependence on lipoprotein apheresis.

· April 2026: Amgen reported three active Phase 3 olpasiran studies spanning secondary prevention, primary prevention, and coronary plaque assessment.

Analyst Perspective

"Clinical adoption will increasingly depend on demonstrating that lipoprotein(a)-lowering therapies provide meaningful cardiovascular risk reduction beyond existing lipid management strategies. Physicians are evaluating long-term outcome data, patient selection criteria, and integration with established preventive care pathways before expanding routine use.

Companies that strengthen clinical evidence, improve diagnostic access, and support coordinated cardiovascular care will be better positioned to drive sustained market adoption."

Access Full Report: https://www.futuremarketinsights.com/reports/lipoprotein-a-lowering-therapies-market

- Anurag Sharma, Principal Consultant for Healthcare, Future Market Insights

About Future Market Insights

Future Market Insights (FMI) is a leading provider of market research and consulting services, offering syndicated and customized research across industries including healthcare, pharmaceuticals, and biotechnology.

Related Reports:

· Endoscopic Imaging Service Market - https://www.futuremarketinsights.com/reports/endoscopic-imaging-service-market

· FDA Breakthrough Device Aortic Stenosis Screening Market - https://www.futuremarketinsights.com/reports/fda-breakthrough-device-aortic-stenosis-screening-market

· Endoluminal & Bronchoscopy Robots Market - https://www.futuremarketinsights.com/reports/endoluminal-and-bronchoscopy-robots-market

Rahul Singh
AVP - Marketing and Growth Strategy
Future Market Insights, Inc.
+91 8600020075
For Sales - sales@futuremarketinsights.com
For Media - Rahul.singh@futuremarketinsights.com
For Web - https://www.futuremarketinsights.com

Future Market Insights (FMI) is a global market intelligence and consulting firm providing comprehensive market research, competitive intelligence, and strategic business insights across industries. The firm delivers detailed forecasts, technology analysis, and data-driven recommendations that support informed decision-making for manufacturers, investors, distributors, and policymakers worldwide.

This release was published on openPR.